STM JOURNALS

Research & Reviews: A Journal of
Toxicology

ISSN: 2231-3834 (Online)
ISSN: 2349-1264 (Print)
Volume 16, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJoT

https://journals.stmjournals.com/rrjot/

Review RRJOT

Drug-Induced Liver Injury: Hepatotoxicity and Treatment – A Literature Review

Shruti Patel[1], Kris Kapadiya[1,*]

Abstract

Drug-induced liver injury (DILI) is a major clinical and regulatory challenge, posing risks to patient safety and drug development worldwide. As the primary organ responsible for xenobiotic metabolism, the liver is particularly susceptible to toxic injury from prescription drugs, over-the-counter medications, herbal products, and dietary supplements. Drug-induced liver injury (DILI) accounts for a substantial proportion of acute liver failure cases and remains a leading cause of post-marketing drug withdrawal. Its pathophysiology is multifactorial, involving mitochondrial dysfunction, oxidative stress, immune-mediated injury, and genetic predispositions. Risk factors, such as age, gender, polypharmacy, comorbidities, and environmental influences, further complicate susceptibility. Diagnosis relies on a combination of clinical suspicion, liver function tests, imaging, histopathology, and causality assessment tools, such as RUCAM, though limitations persist. Biomarkers including miR-122, cytokeratin-18, and HMGB1 show promise for early detection, but require validation. Current management strategies focus on early withdrawal of the offending agent, supportive care, and in severe cases, liver transplantation. Specific antidotes, such as N-acetylcysteine, are effective for acetaminophen toxicity, while herbal agents like silymarin and curcumin are under investigation for hepatoprotective effects. Preventive strategies emphasize pharmacogenomics, monitoring, and personalized medicine approaches. Emerging technologies, including omics platforms, advanced in vitro and in vivo models, and artificial intelligence-driven predictive tools, offer opportunities for better risk assessment and therapeutic innovation. This review highlights the complexity of DILI, summarizes current diagnostic and therapeutic strategies, and emphasizes the need for future research in biomarker development and personalized prevention to improve patient safety and optimize drug development.

Keywords: Drug, RUCAM, HMGB1, immunity, N-acetylcysteine

INTRODUCTION

Drug-induced liver injury (DILI) is an issue of concern for medical professionals, the pharmaceutical sector, and international regulatory bodies like the FDA [1]. The liver's crucial function in the biotransformation (metabolism) of xenobiotics entering the gastrointestinal tract is most likely the primary factor elucidating its vulnerability to adverse drug responses [2]. Liver damage can result from several commercially available medications, herbs, and nutritional supplements. Approximately half of the candidate drugs in preclinical investigations experience drug attrition and exhibit liver effects at supratherapeutic doses [3]. Therefore, it would be preferable to eliminate medications that have a high potential to cause DILI at an early stage of the drug development process [4].

***Author for Correspondence**
Kris Kapadiya
E-mail: kriskapadiya@gmail.com

[1]Researcher, Department of Pharmacy, Gujarat Technological University, School of Pharmacy, Nr. Government Polytechnic K-6 Circle, Gujarat, India

Received Date: October 05, 2025
Accepted Date: December 04, 2025
Published Date: April 15, 2026

Citation: Shruti Patel, Kris Kapadiya. Drug-Induced Liver Injury: Hepatotoxicity and Treatment – A Literature Review. Research & Reviews: A Journal of Toxicology. 2026; 16(1): 1–17p.

BACKGROUND

Numerous prescription drugs, as well as nutritional and herbal supplements, might result in drug-induced liver damage. Early detection and awareness of drug-induced hepatotoxicity, as well

as the creation of a prospective body of trustworthy, comprehensible literature for agents that produce idiosyncratic hepatic harm, depend on accurate reporting of drug-induced liver illness. Significant clinical information can be gained from published case reports that detail adverse events, particularly for uncommon occurrences that clinical trials could miss (Table 1) [5].

Table 1. Reported incidence and prevalence of drug-induced liver injury (DILI) across different populations and study designs [6].

Study/Source	Population/Setting	Reported incidence/ Prevalence	Notes
Prospective study (France)	General population	13.9 per 100,000 inhabitants	Considered a gold standard for true DILI incidence.
Retrospective studies (Sweden & UK)	General population	2–3 cases per 100,000 inhabitants per year	Likely underestimation.
Hospitalized jaundiced patients	Patients hospitalized for jaundice	2–10% had acute hepatic injury from drugs	Based on multiple references [7–11].
Out-patient hepatology clinic (Sweden)	1164 patients	6.6% (77/1164) had DILI	Half were new consults; half were follow-ups after DILI hospitalization.
Hospitalized patients (Switzerland)	Hospitalized patients	1.4% had DILI	Often not listed as a diagnosis or in discharge letters.

About 10% of patients with DILI may not survive the initial injury or may need liver transplantation, while the majority recover fully during the course of the infection. Five to ten percent more people might be at risk for long-term morbidity and mortality as well as chronic damage. More research is necessary to determine how clinical cofactors (like NAFLD) and comorbidities (like diabetes) affect the likelihood of developing chronic DILI. Both early severe result and long-term injury are clearly influenced by host susceptibility variables and hepatotoxic agent heterogeneity. For the time being, the doctor should be aware of the drugs, symptoms, and indicators that point to a higher likelihood of an early, serious outcome (Figure 1) [7].



Figure 1. Timeline of drug-induced liver injury outcomes [8].

Significance

Both patient safety and pharmaceutical viability are impacted by liver injury, especially drug-induced liver injury (DILI), which has a significant impact on clinical practice and drug development. More than one-third of instances of acute liver failure are caused by DILI, which also presents a significant difficulty in clinical trials, frequently resulting in early study termination and post-licensing drug withdrawals [9, 10]. DILI's peculiar characteristics make it difficult to forecast because it often does not show up during preclinical stages, requiring a diagnosis to be made by expert consensus [11, 12]. To improve predictive models and create useful biomarkers, which are still mostly unobtainable, current studies concentrate on comprehending the fundamental mechanisms of DILI [12, 13]. Furthermore, DILI is managed by early offending agent withdrawal and supportive care, underscoring the need for better diagnostic techniques to distinguish DILI from other liver illnesses [9, 12]. Addressing DILI is, therefore, essential to improving medication, safety, and effectiveness in clinical settings.

Objective and Scope

The goal of the review of drug-induced liver injury (DILI) is to present a thorough grasp of its background, diagnostic difficulties, available treatments, and preventative measures, including chemical and herbal methods. Numerous drugs and herbal preparations can cause DILI, which is multifactorial and can have serious clinical consequences such as abrupt liver failure with a high death rate [14, 15]. Clinical suspicion, patient history, and certain evaluation instruments are used to make the diagnosis, and supportive care and, in extreme situations, liver transplantation are the mainstays of treatment [14, 16]. Since little is known about the mechanisms behind DILI, preventive actions are essential. New research is showing that probiotics and gut microbiota can help reduce liver damage [16, 17]. Potential avenues for future research include investigating novel biomarkers and improving knowledge of herbal chemicals that may have hepatoprotective properties, which could result in safer treatment options [18].

PATHOPHYSIOLOGY OF DRUG-INDUCED LIVER INJURY

A complicated interaction between the drug (dosage, duration of therapy, hepatic metabolism, lipophilicity) and the host's variables (age, gender, genetic polymorphisms) is most likely the underlying cause of idiosyncratic DILI, albeit the exact pathophysiology is still unknown [19].

Role of Hepatotoxicity

Hepatotoxicity, the deterioration of liver function due to various substances, can arise from multiple mechanisms, as outlined in recent studies. Key mechanisms include mitochondrial dysfunction, oxidative stress, and immune-mediated damage, often exacerbated by factors such as age, alcohol consumption, and drug interactions [20, 21]. Specific hepatotoxicants, including paracetamol and carbon tetrachloride, induce liver injury through pathways like apoptosis and disruption of metabolic processes [21, 22]. Additionally, lipid overload, particularly in non-alcoholic fatty liver disease (NAFLD), contributes significantly to hepatotoxicity, highlighting the role of inflammation and cell death in liver pathology [23]. Innovative metabolomics approaches are being developed to assess drug-induced hepatotoxicity, allowing for the identification of specific metabolic signatures associated with different toxicity mechanisms [24].

Understanding these diverse pathways is crucial for developing effective therapeutic strategies and minimizing liver damage in clinical settings [20, 24].

In case of Herbal Drug Induced Liver Injury, self-medication, non-specific clinical symptoms, and patients' tendency to conceal their herbal use from doctors make it difficult to prove the hepatotoxicity of herbal medicines. The incorrect identification of plants, incorrect use of plant parts, inappropriate storage, adulteration, and mislabeling are further dangers. Herbal goods' true composition is sometimes unknown, particularly when it comes to multicompany products. When tainted by heavy metals, pesticides, bacteria, or medications, even safe herbs can turn poisonous [25].

Mechanism

The liver is essential for the metabolism and excretion of drugs. Pharmacological-induced liver injury (DILI) can be either idiosyncratic (unpredictable and not explained by known pharmacological features) or intrinsic (dose-dependent and predictable). When a hazardous chemical or metabolite causes an immune response or impairs cell function, it can result in DILI, which causes cell death and hepatitis-like symptoms [26].

There is a molecular connection between intrinsic and idiosyncratic drug-induced liver damage (DILI), and the hepatic metabolism of lipophilic medicines, especially at larger doses, usually initiates both pathways. The production of reactive metabolites from this metabolism leads to several cellular risks, such as endoplasmic reticulum (ER) stress, covalent binding (with or without glutathione [GSH] depletion), activation of stress kinase pathways, and mitochondrial stress, linked to the release of reactive oxygen species (ROS). Depending on the severity and context of the damage, these cellular insults may have some varied effects. Intrinsic DILI can be exacerbated by severe or unabated damage that causes necrosis or apoptosis, which results in cell death. On the other hand, if stress is not fatal, cells might trigger adaptive reactions that enable survival and healing. Idiosyncratic DILI may also be caused by sub-lethal stress co-stimulating an adaptive immune response to drug-protein adducts (haptens) in genetically vulnerable individuals. Innate immune system function in bridging immune activation and sub-lethal stress underscores the intricate relationship between immunological variables and cellular stress responses in the pathophysiology of DILI [25].

Intrinsic hepatotoxicity, or inherent liver toxicity, is a characteristic of several medications and substances that usually manifests in a predictable and dose-dependent way soon after a threshold dose is exceeded. Each person may have a different threshold. Lipophilia allows drugs linked to intrinsic DILI to pass through liver cell membranes and be metabolized into reactive byproducts. Through oxidative stress and stress signaling pathways, these metabolites impair mitochondrial function and upset bile acid balance. Acetaminophen (APAP) toxicity is a well-known example, as it is responsible for around half of all occurrences of acute liver failure (ALF) in the United States and several regions of Europe. Even slightly above-therapeutic dosages might cause liver damage; this is known as "therapeutic misadventure." This demonstrates how repeated high doses can cause increased liver enzymes (like ALT) in otherwise healthy people. Even at lesser doses, factors like alcohol use, fasting, co-medication, and prior medical conditions make people more vulnerable to APAP-induced toxicity [27].

The intricate interaction of xenobiotic, host characteristics, and environmental variables leads to idiosyncratic hepatotoxicity. Aside from genetic predisposition, drug attributes including daily dosage and metabolic profile are becoming significant risk factors for DILI. Hypersensitivity-type reactions can be caused by idiosyncratic damage, as shown by the presence of granulomas, eosinophilia, rash, and fever in the peripheral blood or tissue biopsy. They account for 23–37% of idiosyncratic DILI cases [28].

The pathophysiology of drug-induced liver injury (DILI) involves several key molecular mechanisms that contribute to hepatocellular damage. Central to these mechanisms are oxidative stress and mitochondrial dysfunction, which are exacerbated by the metabolic activation of drugs into reactive intermediates that form covalent adducts with cellular macromolecules, leading to cellular injury and apoptosis [29–31]. Additionally, the activation of innate and adaptive immune responses plays a crucial role, particularly in idiosyncratic DILI, where damage-associated molecular patterns (DAMPs) trigger inflammatory pathways and the presentation of neo-antigens on human leukocyte antigens (HLA) can provoke immune-mediated liver injury [30, 32]. Endoplasmic reticulum (ER) stress also contributes significantly to the pathogenesis, as it disrupts protein folding and cellular homeostasis, further promoting hepatocyte death [33]. Collectively, these mechanisms highlight the complexity of DILI and underscore the need for ongoing research to elucidate their interactions and implications for prevention and treatment [31].

Mitochondrial dysfunction and oxidative stress are critical contributors to drug-induced liver injury (DILI), manifesting through complex biochemical pathways. Mitochondria, essential for energy production, become impaired due to the metabolic activation of drugs, leading to the generation of reactive oxygen species (ROS) that cause oxidative damage to cellular components, including mitochondrial DNA (mtDNA) [34, 35]. This oxidative stress disrupts mitochondrial function, resulting in energy depletion and hepatocyte apoptosis, which can trigger inflammatory responses and further liver damage [30, 36]. Additionally, the imbalance between oxidants and antioxidants during DILI exacerbates cellular injury, promoting the formation of protein adducts that activate immune responses, thereby complicating the injury process [30, 37]. Ultimately, the interplay between mitochondrial dysfunction and oxidative stress underlies the pathogenesis of DILI, highlighting the need for targeted therapeutic strategies to mitigate these effects [34, 37].

Risk Factors for Drug-Induced Liver Injury

Drug-induced liver injury (DILI) is influenced by a variety of risk factors categorized into patient-related, drug-related, and environmental factors. Patient-related factors include advanced age, female sex, and pre-existing liver disease, which increase susceptibility and severity of DILI outcomes [38, 39]. Drug-related factors encompass polypharmacy, specific drug characteristics, and interactions, with certain medications like acetaminophen and herbal supplements being notable culprits [38, 40]. Concomitant medications and herbal supplements can exacerbate liver injury, as they may interact with prescribed drugs or possess inherent hepatotoxic properties [41, 42]. Additionally, comorbidities, such as obesity and diabetes, further complicate the risk landscape, while environmental factors like alcohol consumption can heighten the risk associated with specific drugs [39, 40]. Understanding these multifaceted risk factors is crucial for improving DILI prevention and management strategies (Table 2).

Table 2. Factors influencing susceptibility to drug-induced liver injury (DILI) [43].

Factor category	Details
Age	Older age (>49) increases risk (e.g., isoniazid) – Exceptions: Sodium valproate and erythromycin cause hepatotoxicity more often in children.
Gender	Women more susceptible (e.g., ALF from paracetamol: 74%, idiosyncratic reactions: 67%) Spanish data: gender impact depends on age and injury type.
Concurrent Drugs	• Risk increases with combination therapy (e.g., isoniazid + rifampicin + pyrazinamide). • Delayed cessation of offending drug worsens outcome.
Co-morbid Conditions	HIV, alcoholism, diabetes mellitus, obesity, chronic liver disease increase risk and worsen prognosis.
Genetic Factors	• Immune DILI: HLA associations (e.g., HLA- B*5701 with flucloxacillin). • Non-immune DILI: Associations with CYPs, GST, NAT2, SOD-2, cytokine.
Dose	• Most DILI not dose-dependent. • Risk higher at doses >10 mg/day, but no clear threshold identified.
Treatment Duration	Longer drug exposure before diagnosis linked to higher liver-related morbidity/mortality.
Drug Cessation Timing	Continuing the drug after onset of DILI is associated with chronic liver injury (e.g., 60% in Spanish Registry).
Mechanisms of Injury	• Related to toxic metabolites, oxidative stress, and immune response. • Genetic polymorphisms may affect detox pathways.
Genetic Testing Utility	• Most polymorphisms not clinically predictive yet. • HLA-B*5701 is an exception. • GWAS and SNP analysis may help in future but need large samples.
Severity (Hy's Law)	Severe DILI (Hy's Law) is rare: 1 in 100 to 1 in 10,000 exposures.

Patient-Related Factors

Drug-induced liver injury (DILI) is influenced by various patient-related risk factors that can predispose individuals to this adverse reaction. Understanding these factors is crucial for identifying at-

risk populations and implementing preventive measures. The following sections outline the key patient-related risk factors contributing to DILI.

Age

- *Elderly Patients:* Individuals aged 55 years and older are at a significantly higher risk, with studies indicating an odds ratio of 3.67 for developing DILI in this age group [44].
- *Age-Related Metabolism:* Aging can alter drug metabolism and excretion, increasing susceptibility to liver injury.

Preexisting Conditions

- *Liver Disease:* Patients with preexisting liver conditions have an increased risk of DILI, with an adjusted odds ratio of 1.827 [45].
- *Cardiovascular Disease and Hyperlipidemia:* These conditions also elevate the risk, with odds ratios of 1.465 and 1.884, respectively [45].

Polypharmacy

- *Concomitant Medications:* The use of multiple medications, particularly those known to be hepatotoxic, significantly raises the risk of DILI [38, 44].

Genetic Factors

- *Genetic Variants:* Certain genetic predispositions, such as NAT2, slow acetylator status and specific variants in the ABCB11 gene, have been linked to increased susceptibility to DILI [44]. While these factors highlight the complexity of DILI risk, it is important to note that not all individuals with these risk factors will develop liver injury. The interplay of genetic, environmental, and drug-specific factors can lead to varied outcomes, emphasizing the need for personalized approaches in managing drug therapies.

Drug-Related Factors

Drug-induced liver injury (DILI) is a significant clinical concern, often leading to acute liver failure. Various risk factors contribute to the development of DILI, which can be categorized into genetic and non-genetic factors. Understanding these risk factors is crucial for prevention and management strategies.

Genetic Risk Factors

- *HLA Variants:* Genetic predisposition, particularly human leukocyte antigen (HLA) variants, plays a critical role in idiosyncratic DILI, where immune-mediated mechanisms are involved [19].
- *Metabolic Profiles:* Individual variations in drug metabolism can increase susceptibility to liver injury, particularly for drugs with high lipophilicity [46].

Non-Genetic Risk Factors

- *Age and Gender:* Elderly individuals and females are at higher risk for developing DILI [19, 38].
- *Dietary Supplements:* Herbal and dietary supplements have emerged as common culprits in DILI cases [19].

Concomitant Medications and Herbal Supplements

Drug-induced liver injury (DILI) is influenced by various factors, including concomitant medications, herbal supplements, pre-existing liver disease, and other comorbidities. These factors can exacerbate the risk of liver injury through several mechanisms, which are critical for understanding DILI's pathogenesis.

Factors Associated with DILI

- *Concomitant Medications and Herbal Supplements:* The use of multiple drugs can lead to metabolic interactions, increasing the formation of toxic metabolites. Herbal supplements may also induce or inhibit liver enzymes, altering drug metabolism and enhancing hepatotoxicity [47, 48].

- *Pre-existing Liver Disease:* Patients with liver conditions may have compromised metabolic pathways, making them more susceptible to hepatotoxic agents. This can lead to an accumulation of toxic metabolites and increased oxidative stress [48, 49].
- *Comorbidities:* Conditions, such as diabetes or obesity, can influence liver function and drug metabolism, further increasing the risk of DILI. Inflammation and altered gut microbiota associated with these comorbidities can also contribute to liver injury [48, 50].

Mechanisms of Toxicity

- *Oxidative Stress:* Many drugs induce oxidative stress, leading to cellular damage and mitochondrial dysfunction, which is a common pathway in DILI [49, 50].
- *Immune-Mediated Injury:* Idiosyncratic DILI often involves an immune response triggered by reactive metabolites, which can lead to T cell-mediated liver damage [48, 51].
- *Mitochondrial Dysfunction:* Disruption of mitochondrial function is a significant mechanism of hepatotoxicity, leading to ATP depletion and cell death [50].
- *Common Drugs Associated with Liver Injury:* Commonly implicated drugs and substances associated with drug-induced liver injury (DILI), along with their mechanisms and key references, are summarized in Table 3.

Table 3. Common drugs and substances associated with drug-induced liver injury (DILI), their mechanisms and key references.

Category	Examples	Notes / Mechanism	Key references
Leading cause of acute liver failure Acetaminophen (Intrinsic DILI)	Acetaminophen	(U.S. & Western countries). Dose-related toxicity. Treated with Nacetylcysteine.	[43, 52]
Antibiotics	Amoxicillin-clavulanate (most common in Western registries, frequent), isoniazid, fluoroquinolones	Mechanism varies; hepatotoxic reactions documented.	[46, 52]
NSAIDs	Diclofenac (notable)	Idiosyncratic DILI; often immune-mediated.	[53]
Antidepressants	Various (e.g., tricyclics, SSRIs)	Rare, idiosyncratic reactions; requires monitoring.	
Herbal & Dietary Supplements	Various herbal products & bodybuilding supplements	2nd leading cause in U.S.; incidence tripled in past decade; poorly regulated.	[41, 46, 54]

Drug-induced liver injury is the second leading cause in the U.S.; its incidence has tripled in the past decade; and it remains poorly regulated [41, 46, 54].

DIAGNOSIS OF DRUG-INDUCED LIVER INJURY

Drug-induced liver injury (DILI) is diagnosed primarily through liver function tests (LFTs), which assess the liver's ability to process substances and maintain metabolic functions. Key LFT parameters include alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels, which are critical in identifying liver damage due to drugs. The Roussel Uclaf Causality Assessment Method (RUCAM) is widely recognized for establishing causality in DILI cases, utilizing specific thresholds for ALT and ALP levels to confirm diagnosis. Regular monitoring of LFTs is essential, especially in clinical trials, to differentiate DILI from underlying liver conditions [54, 55–57].

Liver Function Tests

- *Alanine Aminotransferase (ALT):* Levels exceeding 5 times the upper limit of normal (ULN) are indicative of hepatocellular injury [54].
- *Alkaline Phosphatase (ALP):* Levels greater than 2 times the ULN suggest cholestatic injury [54].
- *Aspartate Aminotransferase (AST):* Often assessed alongside ALT to evaluate liver function [55].

- *Causality Assessment:* Tools like RUCAM help determine the likelihood of DILI by evaluating temporal relationships between drug exposure and liver injury [56].
- *Monitoring Protocols:* Regular monitoring of LFTs is essential, especially in clinical trials, to differentiate DILI from underlying liver conditions [57].

While LFTs are crucial for diagnosing DILI, they may not always provide a definitive diagnosis due to overlapping symptoms with other liver diseases. Thus, comprehensive clinical evaluation and additional diagnostic tools may be necessary for accurate assessment [56].

RUCAM Assessment Model

In diagnosing drug-induced liver injury (DILI), there are just two scoring systems, but the one physician actually employ is the Roussel Uclaf Causality Assessment Model (RUCAM). It was made easy enough for clinic use, providing a score of –10 to 14. The greater the score, the stronger the indication that the liver issue is caused by a drug. According to the number, cases are categorized as excluded, unlikely, possible, probable, or highly probable.

RUCAM considers factors, such as the timing of liver damage, the way symptoms evolve after drug withdrawal, risk factors for patients, other potential causes, and what can be expected if the drug is reintroduced. Despite its utility, some aspects remain imprecise. For instance, it states alcohol as a risk factor but not how much, and it assigns points for "known hepatotoxins" without stating which drugs these are. Due to these loopholes, RUCAM is not always reliable – its accuracy is only moderate [7].

Even though RUCAM contains some weaknesses that must be addressed, its algorithmic nature makes it simpler to design electronic versions or to automate the application of this technology. RUCAM stands out from other CAMs that are non-liver-specific, non-element-specific, or non-scoring because it is structured, open, user-friendly, objective, and quantitative diagnostic algorithm according to AI principles. It is also particularly definitive for hepatic damage induced by drugs and herbs [58].

Biomarkers

Drug-induced liver injury (DILI) presents significant diagnostic challenges, necessitating the identification of reliable biomarkers. Traditional markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are commonly used but lack specificity and prognostic value [59, 60]. Recent research has focused on novel biomarkers that can enhance early detection and improve diagnostic accuracy.

Key Biomarkers for DILI Diagnosis

- *Cytokeratin-18 (CK 18):* A promising biomarker indicating hepatocellular injury, with both full-length and cleaved forms showing potential for early DILI diagnosis [60].
- *MicroRNA-122:* This biomarker is associated with liver injury and has shown promise in both diagnosis and prognosis [61].
- *High Mobility Group Box 1 Protein (HMGB1):* Involved in inflammation and cell death, it serves as a potential indicator of liver damage [61].
- *Glutamate Dehydrogenase:* This enzyme is gaining attention for its role in liver function assessment and DILI diagnosis [62].
- *Proteomic Biomarkers:* Recent studies have identified proteins like cytoplasmic aconitate hydratase and arginosuccinate synthase, which demonstrate high diagnostic accuracy in distinguishing DILI from other liver conditions [63].

While these emerging biomarkers show promise, the need for further validation and standardization remains critical to ensure their clinical applicability and reliability in diagnosing DILI [62]. Conversely, the reliance on traditional biomarkers continues due to their established use, despite their limitations, highlighting the ongoing need for advancements in DILI diagnostics.

Imaging Techniques

Drug-induced liver injury (DILI) diagnosis relies on various imaging techniques that enhance detection and assessment of liver damage. These methods are crucial for timely intervention and management of affected patients. The following sections outline the common imaging techniques utilized in diagnosing DILI.

- *Ultrasound (US):* Often the first-line imaging modality, ultrasound can identify liver enlargement, biliary obstruction, and other structural changes associated with DILI.
- *Computed Tomography (CT):* CT scans provide detailed images of the liver and can reveal specific patterns of injury such as sinusoidal obstruction syndrome and focal nodular hyperplasia-like lesions [64].
- *Magnetic Resonance Imaging (MRI):* MRI is useful for assessing liver lesions and can differentiate between various types of liver damage, including drug-induced steatohepatitis [64].
- *Molecular Imaging:* Advanced techniques using chemical probes and nanoprobes, such as those targeting miR-122, allow for sensitive in situ detection of liver injury, correlating signal intensity with the severity of DILI [65, 66].

While these imaging techniques are essential for diagnosing DILI, they may not always provide definitive results. The complexity of liver pathology necessitates a combination of imaging, clinical history, and laboratory tests for accurate diagnosis [67].

Liver Biopsy and Histopathology

Histopathological Patterns

- Liver biopsy can reveal specific histopathological patterns, such as cholestatic hepatitis, lobular disarray, inflammation, and necrosis, which are indicative of DILI [68].
- It allows for the characterization of injury patterns, such as hepatocellular, cholestatic, or mixed-type injuries, which are crucial for accurate diagnosis and management [69, 70].

Clinical Utility

- In cases of antituberculosis therapy-induced DILI, liver biopsy has been shown to confirm DILI in 50% of cases, highlighting its diagnostic value in complex clinical scenarios [69].
- The biopsy findings can help differentiate DILI from other conditions like autoimmune hepatitis and graft-versus-host disease, which is essential for appropriate treatment decisions [70].

Decision-Making and Management

Liver biopsy findings can inform clinical decision-making by providing insights into the severity and potential mechanisms of liver injury, which can guide therapeutic strategies [70].

- Despite its utility, liver biopsy is not included in objective scoring systems for DILI diagnosis, which rely on clinical and temporal relationships [71].

While liver biopsy is a valuable tool in diagnosing DILI, it is not without limitations. The procedure is invasive and carries risks, so its use should be carefully considered based on clinical judgment. Additionally, the variability in DILI presentations and the absence of biopsy findings in scoring systems suggest that liver biopsy should be used selectively, complementing other diagnostic approaches.

TREATMENT STRATEGIES FOR DRUG-INDUCED LIVER INJURY

The management of drug-induced liver injury (DILI) primarily involves the early recognition of hepatotoxicity and the cessation of the offending medication. Current treatment strategies vary in effectiveness, with some showing promise while others remain largely anecdotal. The following sections outline the key treatment modalities and their respective success rates.

Early Intervention and Drug Withdrawal

Immediate cessation of the offending drug is crucial, as it can prevent progression to irreversible liver failure [72, 73]. Monitoring liver enzymes is also considered essential, although its effectiveness outside clinical trials remains debated [72].

Specific Antidotes

- N-acetylcysteine (NAC) is the only specific antidote for acetaminophen toxicity, with a high success rate in preventing liver damage when administered early [72, 74].
- Corticosteroids may be beneficial in cases with autoimmune features, but their efficacy in fulminant failure is unproven [43, 74].

Supportive Treatments

- Ursodeoxycholic acid has been used for cholestatic injury, though evidence of its effectiveness is limited [73, 74].
- Liver support systems are available, but their availability and success rates vary [43, 72].
- Emergency liver transplantation remains an option for severe cases.

While these strategies provide a framework for managing DILI, the lack of specific treatments for many cases highlights the need for ongoing research into more effective therapies and preventive measures.

Herbal Treatment

Herbal treatments for drug-induced liver injury (DILI) have gained attention due to their potential hepatoprotective effects. Various herbs have been identified as beneficial in mitigating liver damage caused by pharmaceuticals, particularly in cases of acetaminophen-induced liver injury. The following sections outline key herbal treatments and their mechanisms.

Common Herbal Treatments

- *Silymarin:* Extracted from milk thistle, it is known for its antioxidant properties and ability to stabilize cell membranes, thus protecting liver cells from toxins [18].
- *Curcumin:* Found in turmeric, curcumin exhibits anti-inflammatory and antioxidant effects, which can help reduce liver inflammation and fibrosis [18].
- *Ginkgo Biloba:* This herb has been shown to enhance liver function and protect against oxidative stress [18].
- *Resveratrol:* Present in grapes, it has hepatoprotective properties that may counteract drug-induced liver damage [18].

The integration of herbal extracts with traditional medications could potentially lead to more effective treatment regimens for DILI, reducing the adverse effects associated with synthetic drugs [75]. Pre-clinical studies suggest that these natural products could be developed into therapeutic agents, offering promising possibilities for clinical implementation [18]. While the potential benefits of combining herbal extracts with traditional medications are promising, it is crucial to approach this integration with caution. The variability in herbal product quality and the lack of standardized dosing can pose challenges. Further research and clinical trials are necessary to establish the safety, efficacy, and optimal use of these combinations in treating drug-induced liver injury [76].

Recommended Dosages of Herbal Agents

- *Silymarin:* A median initial dose of 450 mg has been shown to stabilize liver enzyme levels in patients with DILI, with effective doses ranging from 300–450 mg [77]. A significant percentage of patients (68.63%) exhibited decreased alanine aminotransferase (ALT) levels after treatment, suggesting a positive response to this dosage [77].
- *Hugan Tablets:* In a nationwide database study, normalization rates of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were notably higher in patients treated with Hugan Tablets (50.45% and 67.57%, respectively) compared to controls [78].
- *Herbal Hepatoprotective Agents:* Dosages vary significantly based on the specific herb and the condition being treated. Individualized treatment plans are essential for optimal outcomes [79].

Mechanisms of Action

- *Antioxidant Activity:* Many herbal compounds reduce oxidative stress, a significant contributor to DILI [80].
- *Anti-Inflammatory Effects:* Herbs like curcumin and silymarin help modulate inflammatory pathways, reducing liver inflammation [18].
- *Cell Regeneration:* Some herbs promote liver cell regeneration, aiding recovery from injury [80].

While herbal treatments show promise in managing DILI, caution is warranted due to the potential for hepatotoxicity associated with certain herbs. The indiscriminate use of herbal products can lead to adverse effects, highlighting the need for further research and awareness in both medical and non-medical communities [81, 82].

PREVENTION OF DRUG-INDUCED LIVER INJURY

Pharmacological strategies for preventing Drug-Induced Liver Injury (DILI) focus on early identification, withdrawal of the offending drug, and the use of specific therapeutic agents. The complexity of DILI, due to its idiosyncratic nature and the wide range of drugs involved, necessitates a multifaceted approach. Current strategies emphasize both treatment and prevention, with a strong focus on pharmacogenomics and the development of biomarkers for early detection and risk assessment. Below are the key pharmacological strategies currently employed.

Specific Antidotes and Hepatoprotective Agents

- *N-acetylcysteine (NAC):* Primarily used for acetaminophen-induced liver injury, NAC has shown benefits in some non-acetaminophen DILI cases as well [72, 76].
- *Glutathione and Glycyrrhizin:* These are used as hepatoprotective agents, although their efficacy is largely anecdotal [76].
- *Polyene Phosphatidylcholine and Bicyclol:* These agents are considered for their hepatoprotective properties, though more evidence is needed to confirm their effectiveness [76].

Anticholestatic and Immunosuppressive Agents

- *Ursodeoxycholic Acid and Cholestyramine:* Used to manage cholestatic DILI, with cholestyramine showing evidence-based success, particularly for leflunomide toxicity [72, 76].
- *Glucocorticoids:* Effective in DILI cases with autoimmune or hypersensitivity features [72, 76].

Preventive Strategies

- *Pharmacogenomics:* Human leukocyte antigen genotyping and the discovery of specific biomarkers hold promise for identifying individuals at risk of DILI [72].
- *Monitoring and Early Withdrawal:* Regular monitoring of liver enzymes and early withdrawal of the offending drug are critical in preventing severe outcomes [43, 83].

While these strategies provide a framework for managing DILI, challenges remain, particularly in the development of universally effective treatments. The idiosyncratic nature of DILI and the variability in individual responses to drugs complicate prevention and treatment efforts. Future research into genetic predispositions and the development of more precise biomarkers may enhance the ability to predict and prevent DILI more effectively.

FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES

Drug-induced liver injury (DILI) presents ongoing challenges in clinical practice, necessitating innovative research directions and opportunities. Future research in DILI can be categorized into several key areas that aim to enhance understanding, prevention, and management of this condition.

Enhanced Case Registries and Data Collection

- Development of comprehensive databases to collect well-characterized DILI cases, including biological samples and imaging data, will facilitate better understanding of DILI patterns [84].

- Growing registries can support pharmacoepidemiology studies, leading to improved diagnostic tools and risk markers [83, 84].

Emerging Technologies

Emerging technologies and techniques for discovering and validating novel biomarkers for drug-induced liver injury (DILI) are crucial for improving diagnosis and patient outcomes. Traditional biomarkers like alanine aminotransferase and bilirubin, while widely used, lack specificity and prognostic value, prompting the exploration of new candidates. Recent advances in biomarker discovery have been facilitated by regulatory pathways and collaborative efforts, such as the TransBioLine consortium, which aims to enhance the detection and diagnostic accuracy of DILI through innovative approaches. The following sections outline key emerging technologies and techniques in this field.

Omics Technologies

- Genomics, Proteomics, and Metabolomics: These platforms are employed to identify sensitive and specific biomarkers for hepatotoxicity. They provide comprehensive insights into the molecular changes associated with DILI, aiding in the discovery of novel biomarkers [85].
- MicroRNA Analysis: MicroRNAs, such as miR-122, are being investigated for their potential as biomarkers due to their stability in body fluids and their role in liver injury [62, 85].

Advanced Modeling Systems

- The use of in vitro and in vivo models, including 3D co-cultures and predictive modeling, can elucidate the mechanisms of DILI and improve drug safety testing [86].
- Establishing preclinical models is crucial for predicting hepatotoxicity in humans [84].

Machine Learning and Artificial Intelligence

Machine learning (ML) and artificial intelligence (AI) are increasingly being utilized to predict and prevent drug-induced liver injury (DILI), a significant challenge in drug development. These technologies enhance the ability to assess hepatotoxicity risks early in the drug development process, thereby potentially reducing costly failures. The following sections outline key methodologies and their implications.

In Silico Modeling

- *Mechanistic Approaches:* Tools like DILIsym integrate pharmacokinetic modeling with hepatotoxicity mechanisms, allowing for a comprehensive prediction of DILI risks [87].
- *Data Utilization:* AI models leverage large datasets, including physicochemical properties and biological interactions, to improve prediction accuracy [88].

Natural Language Processing (NLP)

- *Literature Mining:* NLP techniques automate the identification of DILI-related literature, significantly enhancing the efficiency of data collection for predictive modeling [89].
- *Model Performance:* An SVM model achieved an accuracy of 95% in classifying DILI-related publications, demonstrating the effectiveness of combining NLP with ML [89].

Predictive Modeling Techniques

- *Diverse Algorithms:* Various ML methods, including support vector machines and random forests, have been employed to predict DILI severity, achieving high sensitivity and specificity [88].
- *Molecular Representation:* Deep learning approaches excel in encoding molecular properties, which is crucial for accurate DILI risk assessment [90].

While the integration of AI and ML in predicting DILI shows promise, challenges remain such as the need for standardized validation procedures and the limited availability of annotated data. Addressing these issues will be essential for advancing predictive capabilities in drug safety.

Novel Biomarkers and Therapeutics

- Research into new serum biomarkers is essential for enhancing the detection and monitoring of DILI, with potential regulatory acceptance pending large-scale assessments [91].
- Pharmacogenomics and the identification of specific DILI biomarkers may significantly improve prevention strategies and treatment outcomes [72].

While these advancements hold promise, challenges remain in translating research findings into clinical practice, particularly in the timely identification and management of DILI cases.

CONCLUSION

Drug-induced liver injury remains a significant challenge in both clinical practice and pharmaceutical development, profoundly impacting patient safety and the viability of new medications. The intricate pathophysiology of DILI involves multiple molecular mechanisms, including oxidative stress, mitochondrial dysfunction, metabolic drug activation, immune responses, and endoplasmic reticulum stress. Its manifestation is further complicated by a spectrum of patient-related, drug-related, and environmental risk factors. Current management primarily centers on early discontinuation of the offending agent and supportive care, with liver transplantation as a recourse in severe cases. However, the idiosyncratic nature of DILI and the variability in individual responses underscore the urgent need for more effective diagnostic tools and universally effective treatments. Looking ahead, significant research opportunities are emerging to overcome these hurdles. The development of novel biomarkers, facilitated by advanced "omics" technologies, such as genomics, proteomics, and metabolomics, holds immense promise for enhancing early detection and monitoring of DILI. Furthermore, the integration of artificial intelligence and machine learning—through in silico modeling, natural language processing for literature mining, and predictive algorithms like SVM and deep learning—is proving crucial in improving DILI risk assessment and prediction during drug development. Establishing comprehensive case registries and employing advanced in vitro and in vivo modeling systems will continue to deepen our understanding of DILI patterns and mechanisms. Ultimately, sustained research and collaborative efforts in these areas are essential to translate scientific advancements into practical clinical applications, leading to safer medications and improved patient outcomes in the ongoing fight against DILI.

REFERENCES

1. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005 Jun;4(6):489–499.
2. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019 Aug 22;5(1):58.
3. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015 Aug;63(2):503–514.
4. Donato MT, Gallego-Ferrer G, Tolosa L. In vitro models for studying chronic drug-induced liver injury. Int J Mol Sci. 2022 Sep 28;23(19):11428.
5. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010 May;8(5):463–470.
6. Björnsson E. Drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010 Jul;32(1):3–13.
7. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014 May;34(2):134–144.
8. Li M, Wang Y, Lv T, Liu J, Kong Y, Jia J, et al. Mapping the incidence of drug-induced liver injury worldwide: A systematic review and meta-analysis. Res Sq [Preprint]. 2022 [cited 2025 Sep 13]. Available from: https://www.researchsquare.com/article/rs-1557481/v1.
9. Maheshwari A, Ranka S. Drug-induced liver injury. In: Shackelford RT, editor. Shackelford's Surgery of the Alimentary Tract. 8th ed. Philadelphia: Elsevier; 2019. p. 1524–1531.
10. Sandhu N, Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020 May;4(5): 631–645.

11. Regev A. Drug-induced liver injury and drug development: Industry perspective. Semin Liver Dis. 2014 May;34(2):227–239.
12. Weber S, Gerbes AL. Challenges and future of drug-induced liver injury research – Laboratory tests. Int J Mol Sci. 2022 May 27;23(11):6049.
13. Goldring C, Weaver R, Kramer B, Klingmüller U, Oppelt A, van der Water B, et al. Drug-induced liver injury: Mechanism-informed prediction in drug development. In: Comprehensive Medicinal Chemistry III. Oxford: Elsevier; 2017. p. 217–238.
14. Hosack T, Damry D, Biswas S. Drug-induced liver injury: A comprehensive review. Ther Adv Gastroenterol. 2023 Jan;16:17562848231163410.
15. Celikoz M, Hun B, Ozhan G. Drug-induced liver injury (DILI): A short review. Istanb J Pharm. 2017 Aug;47(1):24–29.
16. Chauhan S. Drug-induced liver injury: A systematic review. Asian J Microbiol Biotechnol Environ Sci. 2024;26(2):197–210.
17. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug-induced liver injury: A 2023 update. J Toxicol Environ Health B Crit Rev. 2023 Nov;26(8):442–467.
18. Rani J, Dhull SB, Rose PK, Kidwai MK. Drug-induced liver injury and anti-hepatotoxic effects of herbal compounds: A metabolic mechanism perspective. Phytomedicine. 2024 Jan;122:155142.
19. Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016 Dec;16(6 Suppl):s104–s109.
20. Bertolami MC. Mecanismos de hepatotoxicidade. Arq Bras Cardiol. 2005 Oct;85(Suppl 5):25–30. Available from: http://www.scielo.br/scielo.php?script=sciarttext&pid=S0066-782X2005002400007.
21. Singh G, Sharma RK, Jha N, Mishra A, Chandolia P, Gill K, et al. Overview of the hepatotoxicity inflicted on rodents by diverse animal models and their mechanisms in systematic manners. Authorea Preprints. 2023 [cited 2025 Sep 14]. Available from: https://www.authorea.com/users/639665/articles/654894.
22. Sonar NS, Nagalakshmi NC, S H, Mg H. Hepatotoxicity and hepatotoxicants: A systematic review. Indian J Pharm Pharmacol. 2020 Jan;6(4):107–112.
23. Finelli C. Molecular mechanisms and mediators of hepatotoxicity resulting from excess lipids and non-alcoholic fatty liver disease. Gastrointest Disord. 2023 May;5(2):243–260.
24. Martínez-Sena T, Moro E, Moreno-Torres M, Quintás G, Hengstler JG, Castell JV. Metabolomics-based strategy to assess drug hepatotoxicity and uncover mechanisms involved. Arch Toxicol. 2023 Jun;97(6):1723–1738.
25. Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222–1261.
26. Tiwari V, Shandily S, Albert J, Mishra V, Dikkatwar M, Singh R, et al. Insights into medication-induced liver injury: Understanding and management strategies. Toxicol Rep. 2025 Jun;14:101976.
27. Saleh AK, El-Masry TA, El-Kadem AH, Ashour NA, El-Mahdy NA. Exploring drug-induced liver injury: Comprehensive insights into mechanisms and management of hepatotoxic agents. Future J Pharm Sci. 2025 Mar;11(1):38.
28. Chopra S, Saxena R. Drug-induced liver injury—Perspectives from pathology. Curr Pharmacol Rep. 2018 Jun;4(3):182–192.
29. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug-induced liver injury: A 2023 update. J Toxicol Environ Health B Crit Rev. 2023 Nov;26(8):442–467.
30. Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, et al. Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for clinical practice. Antioxidants (Basel). 2021 Mar;10(3):390.
31. Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, Portincasa P. Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World J Gastroenterol. 2009 Oct;15(39):4865–4876.
32. Ye H, Nelson LJ, del Moral MG, Martínez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol. 2018 Apr;24(13):1373–1385.

33. Wu H, Bao X, Gutierrez AH, Nevzorova YA, Cubero FJ. Role of oxidative stress and endoplasmic reticulum stress in drug-induced liver injury. Explor Dig Dis. 2023 Jun;83–99.
34. LeFort KR, Rungratanawanich W, Song BJ. Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction. Cell Mol Life Sci. 2024 Dec;81(1):34.
35. Xuan W, Song D, Yan Y, Yang M, Sun Y. A potential role for mitochondrial DNA in activation of oxidative stress and inflammation in liver disease. Oxid Med Cell Longev. 2020 Nov;2020:1–10.
36. Pu S, Pan Y, Zhang Q, You T, Yue T, Zhang Y, et al. Endoplasmic reticulum stress and mitochondrial stress in drug-induced liver injury. Molecules. 2023 Jan;28(7):3160.
37. Mosedale M, Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017 Apr;101(4):469–480.
38. Maheshwari A, Ranka S. Drug-induced liver injury. In: Shackelford's Surgery of the Alimentary Tract. 8th ed. Philadelphia: Elsevier; 2019. p. 1524–1531.
39. Suzuki A, Chen M. Epidemiology and risk determinants of drug-induced liver injury: Current knowledge and future research needs. Liver Int. 2025 Apr;45(4):e16146.
40. Vuppalanchi R, Chalasani N. Risk factors for drug-induced liver disease. In: Kaplowitz N, DeLeve LD, editors. Drug-Induced Liver Disease. 3rd ed. Amsterdam: Elsevier; 2013. p. 265–274.
41. Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-induced liver injury: highlights of the recent literature. Drug Saf. 2019 Mar;42(3):365–387.
42. García-Cortés M, Robles-Díaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug-induced liver injury: an update. Arch Toxicol. 2020 Oct;94(10):3381–3407.
43. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut. 2009 Nov;58(11):1555–1564.
44. Cavaco MJ, Alcobia C, Oliveiros B, Mesquita LA, Carvalho A, Matos F, et al. Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment: A study from Portuguese health centers. J Pers Med. 2022 May;12(5):790.
45. Kong X, Guo D, Liu S, Zhu Y, Yu C. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: A matched case-control study. Br J Clin Pharmacol. 2021 Nov; 87(11):4304–4312.
46. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014 Jan;89(1):95–106.
47. Lee WM. Drug-induced hepatotoxicity. Aliment Pharmacol Ther. 1993;7(4):343–355.
48. Gu R, Liang A, Liao G, To I, Shehu A, Ma X. Roles of cofactors in drug-induced liver injury: Drug metabolism and beyond. Drug Metab Dispos. 2022 May;50(5):646–654.
49. Watkins PB. The DILI-Sim initiative: Insights into hepatotoxicity mechanisms and biomarker interpretation. Clin Transl Sci. 2019 Mar;12(2):122–129.
50. Lemasters JJ. Hepatotoxicity due to mitochondrial injury. In: Kaplowitz N, DeLeve LD, editors. Drug-Induced Liver Disease. 3rd ed. Boston: Academic Press; 2013. p. 85–100.
51. Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges. Int J Mol Sci. 2021 Mar;22(6):2954.
52. Lewis JH. Drug-induced and toxic liver disease. In: Friedman LS, Martin P, editors. Handbook of Liver Disease. 4th ed. Philadelphia: Elsevier; 2018. p. 130–157.
53. Hamilton LA, Collins-Yoder A, Collins RE. Drug-induced liver injury. AACN Adv Crit Care. 2016 Oct;27(4):430–440.
54. Yang H, Guo D, Xu Y, Zhu M, Yao C, Chen C, et al. Comparison of different liver test thresholds for drug-induced liver injury: Updated RUCAM versus other methods. Front Pharmacol. 2019 Jul;10:816.
55. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007 Apr;30(4):277–294.
56. Aithal GP. Diagnosing drug-induced liver injury. In: The Liver in Systemic Disease. Chichester: John Wiley & Sons; 2023. p. 243–253.
57. Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, et al. Consensus guidelines: Best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and cirrhosis. Drug Saf. 2021 Feb;44(2):133–165.

58. Teschke R, Danan G. Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): Diagnostic algorithm based on the quantitative Roussel Uclaf causality assessment method (RUCAM). Diagnostics (Basel). 2021 Mar;11(3):458.
59. Humphries C, Dear JW. Novel biomarkers for drug-induced liver injury. Clin Toxicol (Phila). 2023 Aug;61(8):567–572.
60. Korver S, Bowen J, Pearson K, Gonzalez RJ, French N, Park K, et al. Application of cytokeratin-18 as a biomarker for drug-induced liver injury. Arch Toxicol. 2021 Nov;95(11):3435–3448.
61. McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury. In: Ramachandran A, Jaeschke H, editors. Advances in Pharmacology. Vol. 85, Drug-Induced Liver Injury. San Diego: Academic Press; 2019. p. 221–239.
62. Fu S, Wu D, Jiang W, Li J, Long J, Jia C, et al. Molecular biomarkers in drug-induced liver injury: Challenges and future perspectives. Front Pharmacol. 2020 Jan;10:1667.
63. Ravindra KC, Vaidya VS, Wang Z, Federspiel JD, Virgen-Slane R, Everley RA, et al. Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nat Commun. 2023 Mar;14(1):1215.
64. Ichikawa S, Goshima S. Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders. Jpn J Radiol. 2024 Mar;42(3):235–245.
65. Wang QL, Meng LC, Zhao Z, Du JF, Li P, Jiang Y, et al. Ultrasensitive upconverting nanoprobes for in situ imaging of drug-induced liver injury using miR-122 as the biomarker. Talanta. 2024 Jul;274:126108.
66. Jiang T, Rong P, Wang W. Chemical probes for drug-induced liver injury imaging. Future Med Chem. 2020 May;12(9):835–852.
67. Hosack T, Damry D, Biswas S. Drug-induced liver injury: A comprehensive review. Ther Adv Gastroenterol. 2023 Jan;16:17562848231163410.
68. Venkataswamy C, Thomas E, Kartikayan RK. Drug-induced liver injury: A descriptive analysis of histopathological patterns and clinical outcomes. Int J Adv Med Health Res. 2024 Jun;11(1):19–25.
69. Gualano G, Zace D, Mosti S, Mencarini P, Musso M, Libertone R, et al. Utility of liver biopsy in the diagnosis and management of possible drug-induced liver injury in patients receiving antituberculosis therapy: A retrospective study. Infect Dis Rep. 2023 Dec;15(6):735–746.
70. Kleiner DE. Role of liver biopsy in the management of idiosyncratic drug-induced liver injury. Liver Int. 2025 Mar;45(3):e16097.
71. Ahmed T, Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024 Feb;16(2):186–192.
72. Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: A systematic review. Expert Rev Gastroenterol Hepatol. 2016 Apr;10(4):517–536.
73. Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol. 2014 Jun;2(2):74–79.
74. Marino G, Zimmerman HJ, Lewis JH. Management of drug-induced liver disease. Curr Gastroenterol Rep. 2001 Feb;3(1):38–48.
75. Pavithra J, Jiji K, Francis Kevin RS, Govindhan E, Yuvaraj K, Muralidharan P. A critical review on herbal extracts as hepatoprotective agents. J Ayurvedic Herb Med. 2023 Mar;9(1):21–28.
76. Li X, Lao R, Lei J, Chen Y, Zhou Q, Wang T, et al. Natural products for acetaminophen-induced acute liver injury: A review. Molecules. 2023 Nov;28(23):7901.
77. Kohutek F, Bystricky B. Optimal dose of silymarin for the management of drug-induced liver injury in oncology. Mol Clin Oncol. 2023 May;18(5):64.
78. Li J, Zhang J, Xu X, Fang W, Qu S, Jin F, et al. Hugan tablets for the treatment of RUCAM-based drug-induced liver injury: A propensity score matching analysis using a nationwide database. Expert Rev Clin Pharmacol. 2021 Dec;14(12):1543–1550.
79. Rajappa R, Nallupillai P, Krishna K, Ramesh M, Venkatappa A. Exploring the mechanisms and dosages of herbal hepatoprotective agents. Pharmacogn Res. 2024;16(4):706–717.
80. Chang L, Xu D, Zhu J, Ge G, Kong X, Zhou Y. Herbal therapy for the treatment of acetaminophen-associated liver injury: Recent advances and future perspectives. Front Pharmacol. 2020 Mar;11:313.

81. Ballotin VR, Bigarella LG, Brandão ABM, Balbinot RA, Balbinot SS, Soldera J. Herb-induced liver injury: systematic review and meta-analysis. World J Clin Cases. 2021 Jul;9(20):5490–5513.
82. Mullin GE. The use of complementary and alternative medicine for liver disease. Nutr Clin Pract. 2013 Feb;28(1):138–139.
83. Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions. Clin Liver Dis. 2016 Feb;10(1):27–36.
84. Lucena MI, Villanueva-Paz M, Álvarez-Álvarez I, Aithal GP, Björnsson ES, Cakan-Akdogan G, et al. Roadmap to DILI research in Europe: A proposal from COST Action ProEuroDILINet. Pharmacol Res. 2024 Feb;200:107046.
85. Kaur G. Hepatic toxicity biomarkers. In: Gupta RC, editor. Biomarkers in Toxicology. 2nd ed. San Diego: Academic Press; 2019. p. 251–266.
86. Kuna L, Božić I, Kizivat T, Bojanić K, Mršo M, Kralj E, et al. Models of drug-induced liver injury (DILI): current issues and future perspectives. Curr Drug Saf. 2018;13(2):75–83.
87. Lin J, Li M, Mak W, Shi Y, Zhu X, Tang Z, et al. Applications of in silico models to predict drug-induced liver injury. Toxics. 2022 Dec;10(12):788.
88. Rao M, Nassiri V, Alhambra C, Snoeys J, Van Goethem F, Irrechukwu O, et al. AI/ML models to predict the severity of drug-induced liver injury for small molecules. Chem Res Toxicol. 2023 Jul;36(7):1129–1139.
89. Oh JH, Tannenbaum A, Deasy JO. Improved prediction of drug-induced liver injury literature using natural language processing and machine learning methods. Front Genet. 2023 Jul;14:1161047.
90. Li T, Kusko R, Thakkar S, Liu Z, Tong W. Predicting drug-induced liver injury with artificial intelligence: A minireview. In: Su TH, Kao JH, editors. Artificial Intelligence, Machine Learning, and Deep Learning in Precision Medicine in Liver Diseases. San Diego: Academic Press; 2023. p. 233–251.
91. Church RJ, Watkins PB. Serum biomarkers of drug-induced liver injury: Current status and future directions. J Dig Dis. 2019 Jan;20(1):2–10.

